Atrial fibrillation (AF) is an electrophysiological anomaly causing loss of synchronized atrial contractility that puts patients at increased risk of thrombus formation and subsequent cardioembolic ischemic stroke.
1 Anticoagulation is associated with a reduction in the incidence of ischemic stroke in patients with AF.
1 However, the risk of ischemic stroke among patients with AF further increases with comorbidities and is associated with a higher CHA
2DS
2-VASc (cardiac failure or dysfunction, hypertension, age 65-74 [1 point] or ≥75 years [2 points], diabetes mellitus, and stroke, transient ischemic attack or thromboembolism [2 points]–vascular disease, and sex category [female]) score.
1,2 With abnormal homeostasis, patients with end-stage renal disease (ESRD) are at higher risk of ischemic stroke and bleeding events.
3-5 Patients with ESRD also have a higher incidence of AF compared with the general population.
6,7